Primary Hyperoxaluria
Metabolic·MeSH: Hyperoxaluria, Primary
Prevalence
0.5 / 100K
6 drugs in development·4 companies·3 clinical trials
Drug Pipeline by Phase
Approved(2)
Phase 3(2)
Phase 2(1)
| Drug | Company |
|---|---|
| nedosiran | Dicerna Pharmaceuticals Inc (DRNA) |
Preclinical(1)
| Drug | Company |
|---|---|
| chk-336 | CHINOOK THERAPEUTICS, INC. (KDNY) |
Compare drugs
Frequently asked questions
How many drugs are in development for Primary Hyperoxaluria?
BioSniper tracks 6 drugs in development for Primary Hyperoxaluria across 4 companies.
How many clinical trials target Primary Hyperoxaluria?
There are 3 clinical trials targeting Primary Hyperoxaluria tracked by BioSniper.
What is the prevalence of Primary Hyperoxaluria?
The estimated prevalence of Primary Hyperoxaluria is approximately 0.5 per 100,000 population.
Deep-dive into Primary Hyperoxaluria
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis